BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35:1119-1128. [PMID: 22614031 DOI: 10.1007/s00270-012-0394-0] [Cited by in Crossref: 119] [Cited by in F6Publishing: 95] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:75-85. [PMID: 27350573 DOI: 10.1016/j.clinre.2016.05.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
2 Fiorentini G, Sarti D, Carandina R, Mulazzani L, Mincarelli C, Candelari R, Argirò R, Fiorentini C, Aliberti C. A review discussing the use of polyethylene glycol microspheres in the treatment of hepatocellular carcinoma. Future Oncology 2019;15:695-703. [DOI: 10.2217/fon-2018-0425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
4 Cho SM, Chu HH, Kim JW, Kim JH, Gwon DI. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm. Life (Basel) 2021;11:358. [PMID: 33919658 DOI: 10.3390/life11040358] [Reference Citation Analysis]
5 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
6 Sun JY, Yin T, Zhang XY, Lu XJ. Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 2019;234:12116-21. [PMID: 30648254 DOI: 10.1002/jcp.28019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
7 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 16] [Article Influence: 27.0] [Reference Citation Analysis]
8 Forner A, Gilabert M, Bruix J, Raoul JL. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol 2015;12:10. [PMID: 25421282 DOI: 10.1038/nrclinonc.2014.122-c2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
9 Suzuki E, Chiba T, Ooka Y, Ogasawara S, Tawada A, Motoyama T, Kanogawa N, Saito T, Yoshikawa M, Yokosuka O. Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates? World J Gastroenterol 2015;21:8888-93. [PMID: 26269678 DOI: 10.3748/wjg.v21.i29.8888] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36 Suppl 1:124-129. [PMID: 26725909 DOI: 10.1111/liv.13028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 8.4] [Reference Citation Analysis]
11 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
12 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1590] [Article Influence: 707.3] [Reference Citation Analysis]
13 Goda Y, Morimoto M, Irie K, Kobayashi S, Ueno M, Moriya S, Tezuka S, Ohkawa S, Morinaga S, Numata K, Tanaka K, Maeda S. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study. Japanese Journal of Clinical Oncology 2017;47:1151-6. [DOI: 10.1093/jjco/hyx131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Dufour J, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho R. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Annals of Oncology 2013;24:24-9. [DOI: 10.1093/annonc/mdt054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
15 Xiang H, Long L, Yao Y, Fang Z, Zhang Z, Zhang Y. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819830751. [PMID: 30862264 DOI: 10.1177/1533033819830751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
16 Mocan T, Nenu I, Crăciun R, Spârchez Z. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare? J Gastroenterol Hepatol 2021;36:1518-28. [PMID: 33326142 DOI: 10.1111/jgh.15376] [Reference Citation Analysis]
17 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
18 Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol 2020;43:402-10. [PMID: 31705244 DOI: 10.1007/s00270-019-02364-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
20 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 575] [Article Influence: 345.0] [Reference Citation Analysis]
21 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 119] [Article Influence: 27.2] [Reference Citation Analysis]
22 Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. J Vasc Interv Radiol. 2018;29:540-549.e4. [PMID: 29477619 DOI: 10.1016/j.jvir.2017.11.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
24 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
25 Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-264. [PMID: 24937669 DOI: 10.1038/bjc.2014.199] [Cited by in Crossref: 264] [Cited by in F6Publishing: 211] [Article Influence: 37.7] [Reference Citation Analysis]
26 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015;7:2009-2019. [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
27 Bisseret D, Ronot M, Abdel-rehim M, Sibert A, Bouattour M, Castera L, Belghiti J, Vilgrain V. Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. Journal of Vascular and Interventional Radiology 2013;24:1623-31. [DOI: 10.1016/j.jvir.2013.07.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau G, Luca A, del Arbol LR, Leberre M, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology 2016;64:1090-8. [DOI: 10.1016/j.jhep.2016.01.012] [Cited by in Crossref: 296] [Cited by in F6Publishing: 259] [Article Influence: 59.2] [Reference Citation Analysis]
29 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 27.0] [Reference Citation Analysis]
30 Nam HC, Jang B, Song MJ. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World J Gastroenterol 2016;22:8853-61. [PMID: 27833376 DOI: 10.3748/wjg.v22.i40.8853] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
31 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
32 Iezzi R, Pompili M, La Torre MF, Campanale MC, Montagna M, Saviano A, Cesario V, Siciliano M, Annicchiarico E, Agnes S, Giuliante F, Grieco A, Rapaccini GL, De Gaetano AM, Gasbarrini A, Bonomo L, HepatoCATT Study Group for the Multidisciplinary Management of HCC. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis. 2015;47:242-248. [PMID: 25577299 DOI: 10.1016/j.dld.2014.12.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
33 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
34 Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37:165-175. [PMID: 24263774 DOI: 10.1007/s00270-013-0777-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 42] [Article Influence: 8.1] [Reference Citation Analysis]
35 Cardarelli-Leite L, Hadjivassiliou A, Klass D, Chung J, Ho SGF, Lim HJ, Kim PTW, Mujoomdar A, Liu DM. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Curr Oncol 2020;27:S144-51. [PMID: 33343208 DOI: 10.3747/co.27.7171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Carugo D, Capretto L, Roy B, Carboni M, Caine M, Lewis AL, Hill M, Chakraborty S, Zhang X. Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network. Journal of Controlled Release 2015;214:62-75. [DOI: 10.1016/j.jconrel.2015.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
37 Fuster J. Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? Hepat Oncol 2015;2:245-53. [PMID: 30191006 DOI: 10.2217/hep.15.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 90.0] [Reference Citation Analysis]
39 Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, Vaidya S, Monsky WL, Park JO, Bhattacharya R, Hippe DS, Harris WP. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score–Matched Study. Journal of Vascular and Interventional Radiology 2017;28:777-785.e1. [DOI: 10.1016/j.jvir.2017.02.018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 8.8] [Reference Citation Analysis]
40 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 17.3] [Reference Citation Analysis]
41 Gjoreski A, Jovanoska I, Risteski F, Prgova Veljanova B, Nedelkovski D, Dimov V, Popova Jovanovska R, Grozdanovska Angelovska B, Mitrevski N, Dimova B. Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. Eur J Cancer Prev 2021;30:258-66. [PMID: 33038087 DOI: 10.1097/CEJ.0000000000000623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018;24:161-9. [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 35] [Article Influence: 15.0] [Reference Citation Analysis]
43 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
44 Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61:526-536. [PMID: 25212123 DOI: 10.1002/hep.27431] [Cited by in Crossref: 164] [Cited by in F6Publishing: 128] [Article Influence: 27.3] [Reference Citation Analysis]
45 Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, Ingrand P, Tasu JP. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640-1648. [PMID: 26455721 DOI: 10.1007/s00330-015-3982-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
46 Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol 2017;209:722-32. [PMID: 28705059 DOI: 10.2214/AJR.17.18219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
47 Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016;50:418-26. [PMID: 27904450 DOI: 10.1515/raon-2015-0045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
48 Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25:1067-1073. [PMID: 24837982 DOI: 10.1016/j.jvir.2014.03.030] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
49 Young S, Golzarian J. Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature. AJR Am J Roentgenol 2020;215:223-34. [PMID: 32255691 DOI: 10.2214/AJR.19.22098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
51 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 220] [Article Influence: 35.3] [Reference Citation Analysis]
52 Malagari K, Kiakidis T, Pomoni M, Moschouris H, Emmanouil E, Spiridopoulos T, Sotirchos V, Tandeles S, Koundouras D, Kelekis A. Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2016;39:1379-1391. [PMID: 27393274 DOI: 10.1007/s00270-016-1382-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
53 Scaffaro LA, Stella SF, Alvares-Da-Silva MR, Kruel CD. Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol. 2015;7:628-632. [PMID: 25848487 DOI: 10.4254/wjh.v7.i3.628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
54 Shiozawa K, Watanabe M, Ikehara T, Ogino Y, Umakoshi T, Matsukiyo Y, Kogame M, Matsui T, Kikuchi Y, Igarashi Y, Sumino Y. Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Case Rep Oncol 2014;7:739-45. [PMID: 25520649 DOI: 10.1159/000369005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Aliberti C, Carandina R, Lonardi S, Dadduzio V, Vitale A, Gringeri E, Zanus G, Cillo U. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. Journal of Vascular and Interventional Radiology 2017;28:1495-502. [DOI: 10.1016/j.jvir.2017.07.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
56 Miyayama S, Yamashiro M, Sugimori N, Ikeda R, Okimura K, Sakuragawa N. Outcomes of Patients with Hepatocellular Carcinoma Treated with Conventional Transarterial Chemoembolization Using Guidance Software. J Vasc Interv Radiol 2019;30:10-8. [PMID: 30580809 DOI: 10.1016/j.jvir.2018.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
57 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
58 Moschouris H, Malagari K, Papadaki MG, Kornezos I, Stamatiou K, Anagnostopoulos A, Chatzimichael K, Kelekis N. mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. Diagn Interv Radiol. 2014;20:136-142. [PMID: 24317334 DOI: 10.5152/dir.2013.13282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
60 Lewis AL, Dreher MR, O'Byrne V, Grey D, Caine M, Dunn A, Tang Y, Hall B, Fowers KD, Johnson CG, Sharma KV, Wood BJ. DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy. J Mater Sci Mater Med 2016;27:13. [PMID: 26676859 DOI: 10.1007/s10856-015-5629-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
61 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 662] [Article Influence: 156.2] [Reference Citation Analysis]
62 Han S, Zhang X, Zou L, Lu C, Zhang J, Li J, Li M. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS One. 2014;9:e102686. [PMID: 25083860 DOI: 10.1371/journal.pone.0102686] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
63 Xiong F, Cao Y, Guo X, Zhang H, Wang J, Xiong B, Liang B, Zheng C. Improved ADM Penetration Distance and Therapeutic Efficiency in a Rabbit VX2 Liver Cancer Model by Relaxin Infusion Combined with Transcatheter Chemoembolization Through Hepatic Artery. Cancer Manag Res 2020;12:3379-88. [PMID: 32494202 DOI: 10.2147/CMAR.S223993] [Reference Citation Analysis]
64 Weng L, Tseng H, Rostamzadeh P, Golzarian J. In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead. J Mater Sci: Mater Med 2016;27. [DOI: 10.1007/s10856-016-5786-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 24.0] [Reference Citation Analysis]
66 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
67 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 161] [Article Influence: 115.0] [Reference Citation Analysis]
68 Shao G, Zou Y, Lucatelli P, Tsilimigras DI, Shimise S, Kawaguchi T. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med 2021;9:714. [PMID: 33987412 DOI: 10.21037/atm-21-1678] [Reference Citation Analysis]
69 Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Rev Anticancer Ther 2013;13:1157-67. [PMID: 24099626 DOI: 10.1586/14737140.2013.845528] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
70 Zhong J, Lu S, Wang Y, Ma L, Li L. Intermediate-stage HCC—upfront resection can be feasible. Nat Rev Clin Oncol 2015;12:295-295. [DOI: 10.1038/nrclinonc.2014.122-c3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
71 Villani R, Cavallone F, Sangineto M, Fioravanti G, Romano AD, Serviddio G. Management of intermediate-stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy? Int J Clin Pract 2021;75:e13733. [PMID: 32981175 DOI: 10.1111/ijcp.13733] [Reference Citation Analysis]
72 Miyayama S, Yamashiro M, Nagai K, Tohyama J, Kawamura K, Yoshida M, Sakuragawa N. Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging: CT vs Gd-EOB-MRI for recurrent HCC after cTACE. Hepatol Res 2016;46:890-8. [DOI: 10.1111/hepr.12632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
73 Cabibbo G, Tremosini S, Galati G, Mazza G, Gadaleta-Caldarola G, Lombardi G, Antonucci M, Sacco R. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2014;14:831-845. [PMID: 24850249 DOI: 10.1586/14737140.2014.920694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
74 Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129-134. [PMID: 24870698 DOI: 10.1007/s00270-014-0907-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
75 Fuchs K, Bize PE, Denys A, Borchard G, Jordan O. Sunitinib-eluting beads for chemoembolization: Methods for in vitro evaluation of drug release. International Journal of Pharmaceutics 2015;482:68-74. [DOI: 10.1016/j.ijpharm.2014.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
76 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
77 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 850] [Article Influence: 526.7] [Reference Citation Analysis]
78 Szemitko M, Golubinska-Szemitko E, Sienko J, Falkowski A. Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis. Curr Oncol 2021;28:2296-307. [PMID: 34203031 DOI: 10.3390/curroncol28030211] [Reference Citation Analysis]
79 Kairaluoma V, Karjalainen M, Pohjanen VM, Saarnio J, Niemelä J, Huhta H, Helminen O. Treatment trends and outcomes of hepatocellular carcinoma in a single center for 35 years. Minerva Surg 2021;76:252-63. [PMID: 33890436 DOI: 10.23736/S2724-5691.21.08426-1] [Reference Citation Analysis]
80 Dasse KD, Lander MJ, Novelli PM. Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. J Adv Pract Oncol 2016;7:764-78. [PMID: 29670812 DOI: 10.6004/jadpro.2016.7.7.8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol. 2016;8:770-778. [PMID: 27366304 DOI: 10.4254/wjh.v8.i18.770] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
83 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 115] [Article Influence: 38.8] [Reference Citation Analysis]
84 Johnson GE, Monsky WL, Valji K, Hippe DS, Padia SA. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2016;27:1123-9. [PMID: 27321889 DOI: 10.1016/j.jvir.2016.03.046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
85 Mahnken AH. [Transarterial ablative therapy of hepatocellular carcinoma]. Radiologe 2014;54:685-93. [PMID: 25047524 DOI: 10.1007/s00117-014-2655-1] [Reference Citation Analysis]
86 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 8.2] [Reference Citation Analysis]
87 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 729] [Article Influence: 112.9] [Reference Citation Analysis]
88 Elshaarawy O, Gomaa A, Omar H, Rewisha E, Waked I. Intermediate stage hepatocellular carcinoma: a summary review. J Hepatocell Carcinoma. 2019;6:105-117. [PMID: 31372364 DOI: 10.2147/jhc.s168682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
89 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 25.0] [Reference Citation Analysis]
90 Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol 2019;20:34-49. [PMID: 30627020 DOI: 10.3348/kjr.2018.0088] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
91 Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72:626-635. [PMID: 28258743 DOI: 10.1016/j.crad.2017.01.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
92 Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol. 2015;88:20140564. [PMID: 25978585 DOI: 10.1259/bjr.20140564] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
93 Megìas Vericat JE, Garcia Marcos R, Lopez Briz E, Gòmez Munoz F, Ramos Ruiz J, Martinez Rodrigo JJ, Poveda Andrés JL. Trans-arterial Chemoembolization with Doxorubicin-eluting Particles versus Conventional Trans-arterial Chemoembolization in Unresectable Hepatocellular Carcinoma: a Study of Effectiveness, Safety and Costs. Radiologia. 2015;57:496-504. [PMID: 25857250 DOI: 10.1016/j.rx.2015.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
94 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 94] [Article Influence: 19.7] [Reference Citation Analysis]
95 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]